Research Overview

Dr. Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children's Hospital. She has made significant contributions to our understanding of the biochemical and molecular mechanisms that underlie the regulation of tumor growth and progression. Dr. Moses and her laboratory have discovered a number of inhibitors of neovascularization that function at both the transcriptional and translational level some which are being developed for potential clinical use in a variety of human diseases. Named a pioneer in the field of Biomarker Medicine by the Journal of the National Cancer Institute, she created a Proteomics Initiative at Boston Children’s Hospital and has utilized its resources, including an extensive human biorepository and her significant expertise in proteomics, to discover and validate a number of novel, non-invasive, urinary biomarkers for a variety of human cancers as well as non-neoplastic diseases. A number of these biomarkers are being used in clinical trials. She and her team have also engineered novel non-toxic, targeted nanomedicines for the treatment of human cancers and their metastases. These drug delivery systems are engineered to deliver a variety of therapeutic agents including siRNAs, chemotherapies and gene editing systems. A number of these diagnostics and potential therapeutics are included in Dr. Moses’ significant patent portfolio composed of both US and foreign patents.

Dr. Moses’ basic and translational work has been published in such journals as Science, The New England Journal of Medicine, Cell, and Nature Communications, among others. Marsha received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children's Hospital and MIT with Robert Langer, Sc.D. She is the recipient of a number of NIH and foundation grants and awards. Dr. Moses has been recognized with both of Harvard Medical School's mentoring awards, the A. Clifford Barger Mentoring Award (2003) and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty (2009). In 2014, she received the Excellence in Mentoring Award from the Postdoc Association of Boston Children’s Hospital and in 2016, she received their award for Exceptional Mentorship. In 2013, Dr. Moses received the Honorary Member Mentoring Award from the Association of Women Surgeons of the American College of Surgeons. Dr. Moses was elected to the Institute of Medicine (National Academy of Medicine) of the National Academies of the United States in 2008, the National Academy of Inventors in 2013 and the American Institute for Molecular and Biological Engineering in 2018.

About Marsha A. Moses

Dr. Moses completed a National Institutes of Health postdoctoral fellowship at MIT and Boston Children's Hospital with Robert Langer, Sc.D. She is the recipient of a number of NIH and foundation grants and awards. Dr. Moses was elected to the Institute of Medicine (National Academy of Medicine) of the National Academies of the United States in 2008, the National Academy of Inventors in 2013 and the American Institute for Molecular and Biological Engineering in 2018.

Articles from Vector

Representative Publications

  1. Guo P, Liu D, Subramanyam K, Wang B, Yang J, Huang J, Auguste DT*+, Moses MA*+. Nanoparticle elasticity directs tumor uptake. Nature Communications 2018; 9(1):130, January 9. PMID: 29317633. PMCID:PMC5760638 (*These authors contributed equally to this work and are co-last authors.) (+Co-corresponding authors.)
  2. Guo P, Wang B, Liu D, Yang J, Subramanyam K, McCarthy CR, Hebert J, Moses MA*, Auguste DT*. Using atomic force microscopy to predict tumor specificity of ICAM1 antibody-directed nanomedicines. Nano Letters March 2018; 18(4):2254-2262. PMID: 29505261. (*These authors contributed equally and are co-last authors.)
  3. Gordon LB, Campbell SE, Massaro J, D’Agostino RB, Kleinman ME, Kieran MW, Moses MA. A survey of plasma proteins in children with Progeria pre-therapy and on-therapy with Lonafarnib. Pediatric Research May 2018; 83(5):982-992. PMID: 29342131.
  4. Roy R, Dagher A, Butterfield C, Moses, MA. ADAM12 is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling. Molecular Cancer Research, 2017; 15(11):1608-1622. PMID: 28765266 PMCID: PMC5668165.
  5. Guo P*, Yang J*, Bielenberg DR, Dillon D, Zurakowski D, Moses MA+, Auguste DT+. A quantitative method for screening and identifying molecular targets for nanomedicine. J Controlled Release 2017; 263:57-67. pii: S0168-3659(17):30141-4. doi: 10.1016/j.jconrel.2017.03.030. [Epub ahead of print] PMID: 28341549 (*These authors contributed equally to this work.) (+These authors contributed equally to this work and are co-last authors.)
  6. Guo P+, Yang J+, Jia D, Moses MA*,•, Auguste DT*,•. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-Angiogenic Agents for Triple Negative Breast Cancer. Theranostics 2016 Jan 1; 6(1):1-13. PMID: 26722369. PMCID: PMC4679350 (+These authors contributed equally to this work and are co-first authors) (*,•These authors contributed equally to this work and are co-last authors)
  7. Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, Roy R, Sachdev M, Loughlin KR, Moses MA. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer 2015 Apr 11; 15(1):259 PMID: 25884438. PMCID: PMC4433087
  8. Jia D, Huang L, Bischoff J, Moses MA. The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells. FASEB J. 2015 Apr; 29(4):1371-1382 (Epub 2015 July 19) PMID: 25550468. PMCID: PMC4734806
  9. Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer 2014 Oct 28; 111(9):1772-1779 (Epub 2014 Aug 19). PMID: 25137018 PMCID: PMC4453724
  10. Guo P*, Huang J*, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A 2014 Oct 14; 111(41):14710-14715 (Epub 2014 Sep 29 ) (*These authors contributed equally to this work.) PMID: 25267626. PMCID: PMC4205631
  11. Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, Moses MA. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol 2014 Jul; 184(7):2099-20110. PMCID: PMC4076468
  12. Jia D, Hasso SM, Chan J, D’Amore, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood 2013 Jan 24; 121(4): 707-15; Epub 2012 Dec 3. PMCID: PMC3557646 (*Selected for Cover Feature)
  13. Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 2013; 27(1): 45-50. PMCID: PMC3528324
  14. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012 Nov; 181(15):1573-84. PMCID: PMC3483805
  15. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth and metastasis. J Biol Chem 2011 Jun 10; 286(23); Epub 2011 Apr 14. PMCID: PMC3121517
  16. Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, Loop 6, binds IGF-IR. J Biol Chem 2010 Dec 31; 285(53); Epub 2010 Oct 12. PMCID: PMC3009916
  17. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Kung AL, Zurakowski D, Moses MA. Neutrophil gelatinase-associated lipocalin promotes breast cancer progression: mechanistic studies and clinical implications. PNAS 2009; 106(10): 3913-3918. PMCID: PMC2656179
  18. Harper J, Yan L, Louriero R, Wu I, Fang J, D'Amore P, Moses MA. Repression of VEGF expression by the zinc finger transcription factor ZNF24. Cancer Res 2007; 67(18):8736-41.
  19. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V, Louis GW, Anand A, Isakovich N, Hirschfield-Bartek J, Wewer U, Lotz MM, Moses MA. Urinary metalloproteinases: noninvasive biomarkers of breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008; 17(5):1034-42.
  20. Smith ER, Manfredi M, Scott RM, Black P, Moses MA. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery 2007; 60(6):E1148-9.

Researcher Services

Researcher Areas

  • Mechanisms of tumor growth and progression
  • Precision nanotherapeutics
  • Biomarker medicine

Researcher Programs

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Jedinak A, Loughlin KR, Moses MA. Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer. Oncotarget. 2018 Aug 21; 9(65):32534-32550. View abstract
  2. Gordon LB, Campbell SE, Massaro JM, D'Agostino RB, Kleinman ME, Kieran MW, Moses MA. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. Pediatr Res. 2018 May; 83(5):982-992. View abstract
  3. Guo P, Huang J, Zhao Y, Martin CR, Zare RN, Moses MA. Nanomaterial Preparation by Extrusion through Nanoporous Membranes. Small. 2018 May; 14(18):e1703493. View abstract
  4. Huang J, Guo P, Moses MA. A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells. J Vis Exp. 2018 02 16; (132). View abstract
  5. Guo P, Liu D, Subramanyam K, Wang B, Yang J, Huang J, Auguste DT, Moses MA. Nanoparticle elasticity directs tumor uptake. Nat Commun. 2018 01 09; 9(1):130. View abstract
  6. Roy R, Dagher A, Butterfield C, Moses MA. ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling. Mol Cancer Res. 2017 11; 15(11):1608-1622. View abstract
  7. Lin RZ, Lee CN, Moreno-Luna R, Neumeyer J, Piekarski B, Zhou P, Moses MA, Sachdev M, Pu WT, Emani S, Melero-Martin JM. Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng. 2017; 1. View abstract
  8. Shimura T, Ebi M, Yamada T, Yamada T, Katano T, Nojiri Y, Iwasaki H, Nomura S, Hayashi N, Mori Y, Kataoka H, Moses MA, Joh T. Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget. 2017 Apr 25; 8(17):29247-29257. View abstract
  9. Dagher A, Curatolo A, Sachdev M, Stephens AJ, Mullins C, Landis JR, van Bokhoven A, El-Hayek A, Froehlich JW, Briscoe AC, Roy R, Yang J, Pontari MA, Zurakowski D, Lee RS, Moses MA. Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. BJU Int. 2017 07; 120(1):130-142. View abstract
  10. Guo P, Yang J, Bielenberg DR, Dillon D, Zurakowski D, Moses MA, Auguste DT. A quantitative method for screening and identifying molecular targets for nanomedicine. J Control Release. 2017 Oct 10; 263:57-67. View abstract
  11. Guo P, Huang J, Moses MA. Characterization of dormant and active human cancer cells by quantitative phase imaging. Cytometry A. 2017 05; 91(5):424-432. View abstract
  12. Guo P, Yang J, Jia D, Moses MA, Auguste DT. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer. Theranostics. 2016; 6(1):1-13. View abstract
  13. Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45. View abstract
  14. Yang J, Roy R, Jedinak A, Moses MA. Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases. Cancer J. 2015 Jul-Aug; 21(4):327-36. View abstract
  15. Hofmann NA, Yang J, Trauger SA, Nakayama H, Huang L, Strunk D, Moses MA, Klagsbrun M, Bischoff J, Graier WF. The GPR 55 agonist, L-a-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis. Br J Pharmacol. 2015 Aug; 172(16):4107-18. View abstract
  16. Nakayama H, Huang L, Kelly RP, Oudenaarden CR, Dagher A, Hofmann NA, Moses MA, Bischoff J, Klagsbrun M. Infantile hemangioma-derived stem cells and endothelial cells are inhibited by class 3 semaphorins. Biochem Biophys Res Commun. 2015 Aug 14; 464(1):126-32. View abstract
  17. Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, Roy R, Sachdev M, Loughlin KR, Moses MA. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer. 2015 Apr 11; 15:259. View abstract
  18. Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T, Joh T, Moses MA. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila). 2015 Mar; 8(3):240-8. View abstract
  19. Jia D, Huang L, Bischoff J, Moses MA. The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells. FASEB J. 2015 Apr; 29(4):1371-82. View abstract
  20. Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14710-5. View abstract
  21. Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, Moses MA. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol. 2014 Jul; 184(7):2099-110. View abstract
  22. Foradori MJ, Chen Q, Fernandez CA, Harper J, Li X, Tsang PC, Langer R, Moses MA. Matrilin-1 is an inhibitor of neovascularization. J Biol Chem. 2014 May 16; 289(20):14301-9. View abstract
  23. Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT. Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm. 2014 Mar 03; 11(3):755-65. View abstract
  24. Sreenivasan AK, Bachur CD, Lanier KE, Curatolo AS, Connors SM, Moses MA, Comi AM. Urine vascular biomarkers in Sturge-Weber syndrome. Vasc Med. 2013 Jun; 18(3):122-8. View abstract
  25. Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood. 2013 Jan 24; 121(4):707-15. View abstract
  26. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012 Nov; 181(5):1573-84. View abstract
  27. Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. 2013 Jan; 27(1):45-50. View abstract
  28. Guo P, You JO, Yang J, Moses MA, Auguste DT. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials. 2012 Nov; 33(32):8104-10. View abstract
  29. Nikolova A, Ablasser K, Wyler von Ballmoos MC, Poutias D, Kaza E, McGowan FX, Moses MA, Del Nido PJ, Friehs I. Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg. 2012 Nov; 94(5):1509-17. View abstract
  30. Govindarajan B, Willoughby L, Band H, Curatolo AS, Veledar E, Chen S, Bonner MY, Abel MG, Moses MA, Arbiser JL. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vasc Cell. 2012 Jul 05; 4(1):11. View abstract
  31. Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 2012 May 06; 12:169. View abstract
  32. Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011 Dec 21; 3(114):114rv3. View abstract
  33. Roy R, Zurakowski D, Pories S, Moss ML, Moses MA. Potential of fluorescent metalloproteinase substrates for cancer detection. Clin Biochem. 2011 Dec; 44(17-18):1434-9. View abstract
  34. Coticchia CM, Curatolo AS, Zurakowski D, Yang J, Daniels KE, Matulonis UA, Moses MA. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol. 2011 Nov; 123(2):295-300. View abstract
  35. Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, Wight TN, Toole BP, Gordon LB. Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11):1201-7. View abstract
  36. Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33. View abstract
  37. Zhou B, Honor LB, He H, Ma Q, Oh JH, Butterfield C, Lin RZ, Melero-Martin JM, Dolmatova E, Duffy HS, Gise Av, Zhou P, Hu YW, Wang G, Zhang B, Wang L, Hall JL, Moses MA, McGowan FX, Pu WT. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest. 2011 May; 121(5):1894-904. View abstract
  38. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem. 2011 Jun 10; 286(23):20758-68. View abstract
  39. Zhang B, Tsang PC, Pate JL, Moses MA. A role for cysteine-rich 61 in the angiogenic switch during the estrous cycle in cows: regulation by prostaglandin F2alpha. Biol Reprod. 2011 Aug; 85(2):261-8. View abstract
  40. Roy R, Moses MA. ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat. 2012 Feb; 131(3):731-41. View abstract
  41. Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem. 2010 Dec 31; 285(53):41886-95. View abstract
  42. Glasgow CG, Steagall WK, Taveira-Dasilva A, Pacheco-Rodriguez G, Cai X, El-Chemaly S, Moses M, Darling T, Moss J. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med. 2010 Jul; 104 Suppl 1:S45-58. View abstract
  43. Nicksa GA, O'Neil E, Yu DC, Curatolo AS, McNeish BL, Barnewolt CE, Zurakowski D, Buchmiller TL, Moses MA, Rosen S, Fauza DO. Correlation between prenatal urinary matrix metalloproteinase activity and the degree of kidney damage in a large animal model of congenital obstructive uropathy. J Pediatr Surg. 2010 Jun; 45(6):1120-5. View abstract
  44. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23. View abstract
  45. Dudley AC, Udagawa T, Melero-Martin JM, Shih SC, Curatolo A, Moses MA, Klagsbrun M. Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood. 2010 Oct 28; 116(17):3367-71. View abstract
  46. Becker CM, Louis G, Exarhopoulos A, Mechsner S, Ebert AD, Zurakowski D, Moses MA. Matrix metalloproteinases are elevated in the urine of patients with endometriosis. Fertil Steril. 2010 Nov; 94(6):2343-6. View abstract
  47. Novak KB, Le HD, Christison-Lagay ER, Nose V, Doiron RJ, Moses MA, Puder M. Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res. 2010 Mar; 67(3):257-62. View abstract
  48. Nicksa GA, Yu DC, Curatolo AS, McNeish BL, Barnewolt CE, Valim C, Buchmiller TL, Moses MA, Fauza DO. Prenatal urinary matrix metalloproteinase profiling as a potential diagnostic tool in fetal obstructive uropathy. J Pediatr Surg. 2010 Jan; 45(1):70-3. View abstract
  49. Sales VL, Mettler BA, Engelmayr GC, Aikawa E, Bischoff J, Martin DP, Exarhopoulos A, Moses MA, Schoen FJ, Sacks MS, Mayer JE. Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng Part A. 2010 Jan; 16(1):257-67. View abstract
  50. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009 Nov 01; 27(31):5287-97. View abstract
  51. Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009 Aug; 8(15):2347-52. View abstract
  52. Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, Shih SC, Nagy JA, Joyce J, Bogyo M, Kalluri R, Dvorak HF. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009 May 15; 69(10):4537-44. View abstract
  53. Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol. 2010 Feb; 42(2):227-34. View abstract
  54. Manfredi MA, Fox VL, Zurakowski D, Kutok JL, Glickman JN, Moses MA. Matrix metalloproteinases in the urine and tissue of patients with juvenile polyps: potential biomarkers for the presence of polyps. J Pediatr Gastroenterol Nutr. 2009 Apr; 48(4):405-11. View abstract
  55. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A. 2009 Mar 10; 106(10):3913-8. View abstract
  56. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D, Moses MA. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008 Oct 15; 14(20):6610-7. View abstract
  57. Coticchia CM, Yang J, Moses MA. Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw. 2008 Sep; 6(8):795-802. View abstract
  58. Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Aug; 14(8):1091-6. View abstract
  59. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V, Louis GW, Anand A, Isakovich N, Hirshfield-Bartek J, Wewer U, Lotz MM, Moses MA. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1034-42. View abstract
  60. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008 Apr 15; 14(8):2378-86. View abstract
  61. Klagsbrun M, Moses MA. Obituary: M. Judah Folkman (1933-2008). Nature. 2008 Feb 14; 451(7180):781. View abstract
  62. Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M. A critical role for matrix metalloproteinases in liver regeneration. J Surg Res. 2008 Apr; 145(2):192-8. View abstract
  63. Rickert D, Franke RP, Lendlein A, Kelch S, Moses MA. Influence of the surface structure of a multiblock copolymer on the cellular behavior of primary cell cultures of the upper aerodigestive tract in vitro. J Biomed Mater Res A. 2007 Nov; 83(2):558-69. View abstract
  64. Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, Moses MA. Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Res. 2007 Sep 15; 67(18):8736-41. View abstract
  65. Ge G, Fernández CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci U S A. 2007 Jun 12; 104(24):10010-5. View abstract
  66. Smith ER, Manfredi M, Scott RM, Black PM, Moses MA. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery. 2007 Jun; 60(6):E1148-9; discussion E1149. View abstract
  67. Rickert D, Franke RP, Fernández CA, Kilroy S, Yan L, Moses MA. Establishment and biochemical characterization of primary cells of the upper aerodigestive tract. Clin Hemorheol Microcirc. 2007; 36(1):47-64. View abstract
  68. Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, Gura KM, Nose V, Zauscher B, Moses M, Puder M. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol. 2006 Dec; 291(6):G1011-9. View abstract
  69. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006 Jun 15; 354(24):2621-2. View abstract
  70. Fernández CA, Moses MA. Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun. 2006 Jun 23; 345(1):523-9. View abstract
  71. Vogel AM, Smithers CJ, Kozakewich HP, Zurakowski D, Moses MA, Burrows PE, Fauza DO, Fishman SJ. Extracellular matrix dynamics associated with tissue-engineered intravascular sclerotherapy. J Pediatr Surg. 2006 Apr; 41(4):757-62. View abstract
  72. Greene AK, Puder M, Roy R, Arsenault D, Kwei S, Moses MA, Orgill DP. Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg. 2006 Apr; 56(4):418-22. View abstract
  73. Rickert D, Lendlein A, Peters I, Moses MA, Franke RP. Biocompatibility testing of novel multifunctional polymeric biomaterials for tissue engineering applications in head and neck surgery: an overview. Eur Arch Otorhinolaryngol. 2006 Mar; 263(3):215-22. View abstract
  74. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res. 2006 Mar 10; 312(5):608-22. View abstract
  75. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006; (96):223-68. View abstract
  76. Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol. 2006 May; 101(3):204-13. View abstract
  77. Benisty JI, Folkman J, Zurakowski D, Louis G, Rich S, Langleben D, Moses MA. Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. Chest. 2005 Dec; 128(6 Suppl):572S. View abstract
  78. Fernández CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005 Aug 01; 11(15):5390-5. View abstract
  79. Marler JJ, Fishman SJ, Kilroy SM, Fang J, Upton J, Mulliken JB, Burrows PE, Zurakowski D, Folkman J, Moses MA. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics. 2005 Jul; 116(1):38-45. View abstract
  80. Rickert D, Lendlein A, Kelch S, Franke RP, Moses MA. [Cell proliferation and cellular activity of primary cell cultures of the oral cavity after cell seeding on the surface of a degradable, thermoplastic block copolymer]. Biomed Tech (Berl). 2005 Apr; 50(4):92-9. View abstract
  81. Zhang B, Yan L, Tsang PC, Moses MA. Matrix metalloproteinase-2 (MMP-2) expression and regulation by tumor necrosis factor alpha (TNFalpha) in the bovine corpus luteum. Mol Reprod Dev. 2005 Feb; 70(2):122-32. View abstract
  82. Rickert D, Lendlein A, Kelch S, Moses MA, Franke RP. Expression of MMPs and TIMPs in primary epithelial cell cultures of the upper aerodigestive tract seeded on the surface of a novel polymeric biomaterial. Clin Hemorheol Microcirc. 2005; 32(2):117-28. View abstract
  83. Shukla A, Dunn AR, Moses MA, Van Vliet KJ. Endothelial cells as mechanical transducers: enzymatic activity and network formation under cyclic strain. Mech Chem Biosyst. 2004 Dec; 1(4):279-90. View abstract
  84. Greene AK, Puder M, Roy R, Kilroy S, Louis G, Folkman J, Moses MA. Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy. Transplantation. 2004 Oct 27; 78(8):1139-44. View abstract
  85. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem. 2004 Dec 03; 279(49):51323-30. View abstract
  86. Chang LK, Garcia-Cardeña G, Farnebo F, Fannon M, Chen EJ, Butterfield C, Moses MA, Mulligan RC, Folkman J, Kaipainen A. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11658-63. View abstract
  87. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Ménard C, Camphausen K. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004 Feb 01; 22(3):499-506. View abstract
  88. Moses MA, Harper J, Fernández CA. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep. 2004 Jan; 6(1):42-8. View abstract
  89. Munavalli G, Reisenauer A, Moses M, Kilroy S, Arbiser JL. Weight loss-induced calciphylaxis: potential role of matrix metalloproteinases. J Dermatol. 2003 Dec; 30(12):915-9. View abstract
  90. Zhang B, Moses MA, Tsang PC. Temporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteum. Reprod Biol Endocrinol. 2003 Nov 07; 1:85. View abstract
  91. Moses MA, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell. 2003 Nov; 4(5):337-41. View abstract
  92. Fernández CA, Butterfield C, Jackson G, Moses MA. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem. 2003 Oct 17; 278(42):40989-95. View abstract
  93. Solan A, Mitchell S, Moses M, Niklason L. Effect of pulse rate on collagen deposition in the tissue-engineered blood vessel. Tissue Eng. 2003 Aug; 9(4):579-86. View abstract
  94. Wu I, Moses MA. BNF-1, a novel gene encoding a putative extracellular matrix protein, is overexpressed in tumor tissues. Gene. 2003 Jun 05; 311:105-10. View abstract
  95. Camphausen K, Moses MA, Ménard C, Sproull M, Beecken WD, Folkman J, O'Reilly MS. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003 Apr 15; 63(8):1990-3. View abstract
  96. Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, Louis G, Moses M, Arbiser JL. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem. 2003 Mar 14; 278(11):9790-5. View abstract
  97. Rickert D, Moses MA, Lendlein A, Kelch S, Franke RP. The importance of angiogenesis in the interaction between polymeric biomaterials and surrounding tissue. Clin Hemorheol Microcirc. 2003; 28(3):175-81. View abstract
  98. Moses MA, O'Reilly MS. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. Methods Mol Med. 2003; 74:375-90. View abstract
  99. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002 Oct; 110(7):923-32. View abstract
  100. Zhang B, Yan L, Moses MA, Tsang PC. Bovine membrane-type 1 matrix metalloproteinase: molecular cloning and expression in the corpus luteum. Biol Reprod. 2002 Jul; 67(1):99-106. View abstract
  101. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):715-20. View abstract
  102. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001 Oct 05; 276(40):37258-65. View abstract
  103. Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res. 2001 Aug 01; 61(15):5731-5. View abstract
  104. Yan L, Moses MA. A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma. Am J Pathol. 2001 Apr; 158(4):1185-90. View abstract
  105. Stock UA, Wiederschain D, Kilroy SM, Shum-Tim D, Khalil PN, Vacanti JP, Mayer JE, Moses MA. Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures. J Cell Biochem. 2001 Mar 26; 81(2):220-8. View abstract
  106. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001 Mar 01; 61(5):2207-11. View abstract
  107. Wu I, Moses MA. Cloning of a cDNA encoding an isoform of human protein phosphatase inhibitor 2 from vascularized breast tumor. DNA Seq. 2001; 11(6):515-8. View abstract
  108. Stock UA, Sakamoto T, Hatsuoka S, Martin DP, Nagashima M, Moran AM, Moses MA, Khalil PN, Schoen FJ, Vacanti JP, Mayer JE. Patch augmentation of the pulmonary artery with bioabsorbable polymers and autologous cell seeding. J Thorac Cardiovasc Surg. 2000 Dec; 120(6):1158-67; discussion 1168. View abstract
  109. LaMontagne KR, Moses MA, Wiederschain D, Mahajan S, Holden J, Ghazizadeh H, Frank DA, Arbiser JL. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 2000 Dec; 157(6):1937-45. View abstract
  110. Yan L, Moses MA, Huang S, Ingber DE. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci. 2000 Nov; 113 ( Pt 22):3979-87. View abstract
  111. Wu I, Moses MA. Angiogenic molecules and mechanisms in breast cancer. Curr Oncol Rep. 2000 Nov; 2(6):566-71. View abstract
  112. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):3884-9. View abstract
  113. Scrivani SJ, Moses M, Donoff RB, Kaban LB. Taste perception after lingual nerve repair. J Oral Maxillofac Surg. 2000 Jan; 58(1):3-5; discussion 5-6. View abstract
  114. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 1999 Dec 15; 59(24):6052-6. View abstract
  115. Shum-Tim D, Stock U, Hrkach J, Shinoka T, Lien J, Moses MA, Stamp A, Taylor G, Moran AM, Landis W, Langer R, Vacanti JP, Mayer JE. Tissue engineering of autologous aorta using a new biodegradable polymer. Ann Thorac Surg. 1999 Dec; 68(6):2298-304; discussion 2305. View abstract
  116. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999 Oct 08; 274(41):29568-71. View abstract
  117. Gobet R, Bleakley J, Cisek L, Kaefer M, Moses MA, Fernandez CA, Peters CA. Fetal partial urethral obstruction causes renal fibrosis and is associated with proteolytic imbalance. J Urol. 1999 Sep; 162(3 Pt 1):854-60. View abstract
  118. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol. 1999 Aug; 6(8):R217-24. View abstract
  119. Kräling BM, Wiederschain DG, Boehm T, Rehn M, Mulliken JB, Moses MA. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J Cell Sci. 1999 May; 112 ( Pt 10):1599-609. View abstract
  120. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, Flynn E, Sytkowski A, Tao T, Langer R. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2645-50. View abstract
  121. Dethlefsen SM, Raab G, Moses MA, Adam RM, Klagsbrun M, Freeman MR. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem. 1998 May 01; 69(2):143-53. View abstract
  122. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998 Apr 01; 58(7):1395-9. View abstract
  123. Wu I, Moses MA. Molecular cloning and expression analysis of the cDNA encoding rat tissue inhibitor of metalloproteinase-4. Matrix Biol. 1998 Jan; 16(6):339-42. View abstract
  124. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 1997 Dec 12; 272(50):31730-7. View abstract
  125. Peters CA, Freeman MR, Fernandez CA, Shepard J, Wiederschain DG, Moses MA. Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. Am J Physiol. 1997 Jun; 272(6 Pt 2):R1960-5. View abstract
  126. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A. 1997 Feb 04; 94(3):861-6. View abstract
  127. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997; 15(3):180-9. View abstract
  128. Huang SH, Adamis AP, Wiederschain DG, Shima DT, Shing Y, Moses MA. Matrix metalloproteinases and their inhibitors in aqueous humor. Exp Eye Res. 1996 May; 62(5):481-90. View abstract
  129. Goldberg MJ, Moses MA, Tsang PC. Identification of matrix metalloproteinases and metalloproteinase inhibitors in bovine corpora lutea and their variation during the estrous cycle. J Anim Sci. 1996 Apr; 74(4):849-57. View abstract
  130. Moses MA, Marikovsky M, Harper JW, Vogt P, Eriksson E, Klagsbrun M, Langer R. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem. 1996 Mar 01; 60(3):379-86. View abstract
  131. Wu I, Moses MA. Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3 (TIMP-3). Gene. 1996 Feb 12; 168(2):243-6. View abstract
  132. Moses MA, Klagsbrun M, Shing Y. The role of growth factors in vascular cell development and differentiation. Int Rev Cytol. 1995; 161:1-48. View abstract
  133. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21; 79(2):315-28. View abstract
  134. Rosenthal RA, Moses MA, Shintani Y, Megyesi JF, Langer R, Folkman J. Purification and characterization of two collagenase inhibitors from mouse sarcoma 180 conditioned medium. J Cell Biochem. 1994 Sep; 56(1):97-105. View abstract
  135. Braunhut SJ, Moses MA. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem. 1994 May 06; 269(18):13472-9. View abstract
  136. Moses MA, Shing Y. Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma. Biochem Biophys Res Commun. 1994 Feb 28; 199(1):418-24. View abstract
  137. Sasisekharan R, Moses MA, Nugent MA, Cooney CL, Langer R. Heparinase inhibits neovascularization. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1524-8. View abstract
  138. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 1994; 59:471-82. View abstract
  139. Moses MA. A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol. 1993 Mar-Apr; 11 Suppl 8:S67-9. View abstract
  140. Moses MA, Sudhalter J, Langer R. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol. 1992 Oct; 119(2):475-82. View abstract
  141. Moses MA, Langer R. Metalloproteinase inhibition as a mechanism for the inhibition of angiogenesis. EXS. 1992; 61:146-51. View abstract
  142. Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem. 1991 Nov; 47(3):230-5. View abstract
  143. Moses MA, Langer R. Inhibitors of angiogenesis. Biotechnology (N Y). 1991 Jul; 9(7):630-4. View abstract
  144. Langer R, Moses M. Biocompatible controlled release polymers for delivery of polypeptides and growth factors. J Cell Biochem. 1991 Apr; 45(4):340-5. View abstract
  145. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990 Jun 15; 248(4961):1408-10. View abstract